Jazz Pharmaceuticals (JAZZ): Raising PT After Vyxeos Expert Feedback - BMO

September 7, 2016 9:18 AM EDT
Get Alerts JAZZ Hot Sheet
Price: $123.88 -0.43%

Rating Summary:
    28 Buy, 4 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade JAZZ Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

BMO Capital analyst, Gary Nachtman, reiterated his Outperform rating on shares of Jazz Pharmaceuticals (NASDAQ: JAZZ) after he received very positive feedback from two physician experts in AML regarding the prospects for Vyxeos as a new treatment paradigm.

The analyst stated "They were extremely enthusiastic based on the impressive Phase 3 data. Thus, we are raising our Vyxeos forecasts and bumping up our target to $195. We reiterate our Outperform rating. If the generic Xyrem overhang is ultimately lifted at some point (we are optimistic it will be), we believe underappreciated products like Vyxeos will become more of a focus for investors and help drive higher numbers and multiple expansion."

The improved opportunity led the analyst to increase his price target to $195 from $193.

For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.

Shares of Jazz Pharmaceuticals closed at $121.42 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

BMO Capital

Add Your Comment